SHARE PURCHASE AGREEMENTShare Purchase Agreement • August 7th, 2018 • Axovant Sciences Ltd. • Pharmaceutical preparations • New York
THIS SHARE PURCHASE AGREEMENT (“Agreement”), dated as of June 5, 2018, is made by and between ROIVANT SCIENCES LTD. (the “Investor”), a Bermuda exempted company, with its principal place of business at Suite 1, 3rd Floor, 11-12 St. James’s Square, London SW1Y 4LB, United Kingdom, and AXOVANT SCIENCES LTD. (the “Company”), a Bermuda exempted company, with its principal place of business at Suite 1, 3rd Floor, 11-12 St. James’s Square, London SW1Y 4LB, United Kingdom. The Investor and the Company are collectively referred to as “the Parties.”
AMENDED AND RESTATED INFORMATION SHARING AND COOPERATION AGREEMENT by and among AXOVANT SCIENCES LTD., AND ROIVANT SCIENCES LTD. Dated as of June 5, 2018Sharing and Cooperation Agreement • August 7th, 2018 • Axovant Sciences Ltd. • Pharmaceutical preparations • New York
WHEREAS, the Parties wish to amend and restate the Original Agreement in its entirety, effective as of the Closing Date (as defined in that certain Share Purchase Agreement, dated as of June 5, 2018, by and between Roivant and the Company) (the “Effective Date”).
ContractLicence Agreement • August 7th, 2018 • Axovant Sciences Ltd. • Pharmaceutical preparations
[***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Section 240.24b-2.
